Homocysteine as a cardiovascular marker and risk factor

In context of cardiovascular secondary prevention the D.A.C.H.-Liga (union of scientists from Germany, Austria, and Switzerland doing research on the topic homocysteine) demands that the homocysteine level should be measured and recommends a substitution of folic acid above a value of 10 mu mol/l. Numerous studies have proven the therapy's positive effect. Although a threshold could not be aquired in any study there seems to be an association between the homocysteine level and an increased cardiovascular risk. Homocysteine is not only a marker, but also a reason of cardiovascular mortality and morbidity. Further detailed statements concerning homocysteine therapy can be made after completing of current research.